Calamos Advisors LLC grew its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 198.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 106,979 shares of the company's stock after acquiring an additional 71,120 shares during the period. Calamos Advisors LLC owned about 0.05% of Cellebrite DI worth $2,357,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also made changes to their positions in the company. Quarry LP purchased a new position in shares of Cellebrite DI in the third quarter valued at about $27,000. Advisors Asset Management Inc. lifted its position in shares of Cellebrite DI by 130.5% in the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company's stock valued at $52,000 after acquiring an additional 1,742 shares in the last quarter. Pathway Financial Advisers LLC lifted its position in shares of Cellebrite DI by 1,583.8% in the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock valued at $74,000 after acquiring an additional 4,118 shares in the last quarter. R Squared Ltd purchased a new position in shares of Cellebrite DI in the fourth quarter valued at about $100,000. Finally, Venturi Wealth Management LLC lifted its position in shares of Cellebrite DI by 28.6% in the third quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company's stock valued at $152,000 after acquiring an additional 2,000 shares in the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on CLBT. JPMorgan Chase & Co. boosted their target price on Cellebrite DI from $22.00 to $24.00 and gave the stock an "overweight" rating in a research report on Monday, December 16th. Craig Hallum boosted their target price on Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Finally, Needham & Company LLC boosted their target price on Cellebrite DI from $21.00 to $28.00 and gave the stock a "buy" rating in a research report on Wednesday, January 22nd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI currently has an average rating of "Buy" and a consensus target price of $21.57.
View Our Latest Analysis on Cellebrite DI
Cellebrite DI Stock Up 0.8 %
NASDAQ CLBT traded up $0.20 during trading hours on Friday, hitting $25.41. 2,173,997 shares of the company were exchanged, compared to its average volume of 1,762,856. The stock has a 50-day moving average price of $22.31 and a 200 day moving average price of $18.81. Cellebrite DI Ltd. has a 52 week low of $8.91 and a 52 week high of $26.30. The stock has a market cap of $5.23 billion, a PE ratio of -16.39, a price-to-earnings-growth ratio of 3.72 and a beta of 1.47.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The company had revenue of $106.90 million for the quarter, compared to analysts' expectations of $102.06 million. During the same quarter in the prior year, the firm earned $0.09 earnings per share. Cellebrite DI's revenue was up 27.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
